EUCTR2018-000366-11-ES进行中（未招募）1 期
A phase III randomized, double-blinded trial of platinum-based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal or peritoneal cancer and platinum treatment-free interval (TFIp) >6 months. - ANITA
Grupo Español de Investigación en Cáncer de Ovario (GEICO)0 个研究点目标入组 80 人开始时间: 2018年8月2日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Patients = 18 years old
- •2. Life expectancy =3 months
- •3. Signed informed consent and ability to comply with treatment and follow-up
- •4. Histologically confirmed diagnosis (cytology alone excluded) of high- grade serous or endometrioid ovarian, primary peritoneal or tubal carcinoma. In addition, mixed histologies with predominat high grade serous or endometrioid, or undifferentiated adenocarcinoma of the ovary are allowed
- •5. BRCA mutational status is known (germline or somatic)
- •6. Relapsed disease more than 6 months after the last platinum dose:
- •7. No more than 2 prior lines of chemotherapy are allowed, and the last one must contain a platinum-based regimen
- •8. At least one measurable lesion to assess response by RECIST v1.1 criteria.
- •9. Archival tumor sample must be available.
- •10. Performance status determined by ECOG score of 0-1
- •11. Patients must have normal organ and bone marrow function:
- •- Haemoglobin =10.0 g/dL
- •- Absolute neutrophil count (ANC) =1.5 x 109/L
- •- Lymphocyte count =0.5 × 109/L
- •- Platelet count =100 x 109/L
- •- Total bilirubin =1.5 x institutional upper limit of normal (ULN)
- •- Serum albumin =2.5 g/dL
- •- Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) =2.5 x ULN, unless liver metastases are present in which case they must be =5 x ULN
- •- Serum creatinine =1.5 x institutional ULN or calculated creatinine clearance = 30 mL/min using the Cockcroft-Gault equation
- •- Patients not receiving anticoagulant medication must have an International Normalized Ratio (INR) =1.5 and an Activated ProThrombin Time (aPTT) =1.5 x ULN.
- •12. Negative Test Results for Hepatitis
- •13. Toxicities related to previous treatments must be recovered to < grade 2 (with the exception of alopecia)
- •14. Female participants must be postmenopausal (= 12 months of non-therapy-induced amenorrhoea; patients who have been amenorrhoeic for <2 years without history of a hysterectomy and oophorectomy must have a follicle stimulating hormone value in the postmenopausal range upon screening evaluation) or surgically sterile (absence of ovaries and/or uterus, or who received therapeutic radiation to the pelvis) or otherwise have a negative serum pregnancy test within 7 days of the first study treatment and agree to abstain from heterosexual intercourse or use single or combined contraceptive methods that result in a failure rate of <1% per year during the whole treatment period of the study and for at least 180 days after the last dose of study treatment
- •15. Participant must agree to not donate blood during the study or for 90 days after the last dose of study treatment.
- •16. Participant must agree to not breastfeed during the study or for 180 days after the last dose of study treatment.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 354
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 60
排除标准
- •1. Non-epithelial tumor of the ovary, the fallopian tube or the peritoneum
- •2. Ovarian tumors of low malignant potential or low grade
- •3. Other malignancy within the last 5 years except curatively treated non-melanoma skin cancer, in situ cancer of the cervix and ductal carcinoma in situ (DCIS)
- •4. Major surgery or patients who have not completely recovered from the effects of any major surgery at randomization
- •5. Core biopsy or other minor surgical procedure.
- •6. Administration of other chemotherapy drugs, anticancer therapy or anti-neoplastic hormonal therapy, or treatment with other investigational agents or devices
- •7. Palliative radiotherapy
- •8. Current or recent chronic use of aspirin or clopidogrel
- •9. Clinically significant cardiovascular disease
- •10. Resting ECG with QTc >470 msec on 2 or more time points within a 24 hour period or family history of long QT syndrome
- •11. Left ventricular ejection fraction defined by MUGA/ECHO below the institutional lower limit of normal
- •12. History or clinical suspicion of brain metastases or spinal cord compression. CT/MRI of the brain is mandatory in case of suspected brain metastases.
- •13. History or evidence upon neurological examination of central nervous system (CNS) disorders
- •14. Current, clinically relevant bowel obstruction, including sub-occlusive disease, related to underlying disease
- •15. Uncontrolled tumor-related pain
- •16. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
- •17. Uncontrolled hypercalcemia or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab
- •18. Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment related complications
- •19. Pregnant or lactating women
- •20. Simultaneously receiving therapy in any interventional clinical trial.
- •21. Prior treatment with CD137 agonists or immune checkpoint stimulating or blockade therapies, such as anti-PD1, anti-PDL1 or anti-CTLA4 therapeutic antibodies
- •22. Treatment with systemic immunostimulatory agents
- •23. Treatment with systemic corticosteroids or other systemic immunosuppressive medications
- •24. History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with anti-phospholipid syndrome, Wegener’s granulomatosis, Sjögren’s syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.
- •25. History of idiopathic pulmonary fibrosis, drug-induced pneumonitis, organizing pneumonia, or evidence of active pneumonitis.
- •26. Immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV)
- •27. Signs or symptoms of infection within 2 weeks prior to Cycle 1, Day 1
- •28. Administration of a live, attenuated vaccine or anticipation that it will be administered at any time during the treatment period of the study
- •29. History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
- •30. Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or to any component of the atezolizumab formulation or allergy to any o
研究者
相似试验
进行中（未招募）
1 期
Double-blinded trial of platinum-based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal or peritoneal cancer.Recurrent ovarian, tubal or peritoneal cancerMedDRA version: 20.0Level: LLTClassification code 10033130Term: Ovarian cancer NOSSystem Organ Class: 100000004864EUCTR2018-000366-11-FRGrupo Español de Investigación en Cáncer de Ovario (GEICO)414
进行中（未招募）
1 期
Double-blinded trial of platinum-based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal or peritoneal cancer.Recurrent ovarian, tubal or peritoneal cancerMedDRA version: 21.1Level: LLTClassification code 10033131Term: Ovarian carcinomaSystem Organ Class: 100000004864EUCTR2018-000366-11-ITGrupo Español de Investigación en Cáncer de Ovario (GEICO)414
进行中（未招募）
1 期
Double-blinded trial of platinum-based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal or peritoneal cancer.Recurrent ovarian, tubal or peritoneal cancerMedDRA version: 20.0Level: LLTClassification code 10033130Term: Ovarian cancer NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000366-11-DEGrupo Español de Investigación en Cáncer de Ovario (GEICO)90
进行中（未招募）
1 期
Chemo +/- Pembrolizumab (MK-3475) as Perioperative Therapy for Stage II, IIIA-Resectable IIIB (N2) NSCLCeoadjuvant/Adjuvant treatment for participants with Resectable Stage II or IIIA-B (N2) NSCLCMedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864CTIS2023-504820-24-00Merck Sharp & Dohme LLC786
进行中（未招募）
1 期
Chemo +/- Pembrolizumab (MK-3475) as Perioperative Therapy for Resectable Stage IIB or IIIA NSCLCeoadjuvant/Adjuvant treatment for participants with Resectable Stage IIB or IIIA NSCLCMedDRA version: 20.0Level: PTClassification code 10029518Term: Non-small cell lung cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: PTClassification code 10029520Term: Non-small cell lung cancer stage IIIASystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-001832-21-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.786